In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

GLP-1RAs have shown considerable effects for weight loss to treat obesity. A recent Phase 3 trial published in Nature Medicine found that tirzepatide led to additional weight loss of over 20% when ...

In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A new study published JAMA Ophthalmology has brought attention to a series of vision problems observed in patients taking ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.